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Background: Recent work has indicated that dimerization is important in the 
mode of action of the vancomycin group of glycopeptide antibiotics. NMR studies 
have shown that one member of this group, ristocetin A, forms an asymmetric 
dimer with two physically different binding sites for cell wall peptides. Ligand 
binding by ristocetin A and dimerization are slightly anti-cooperative. In contrast, 
for the other glycopeptide antibiotics of the vancomycin group that have been 
examined so far, binding of cell wall peptides and dimerization are cooperative. 
Results: Here we show that the two halves of the asymmetric homodimer 
formed by ristocetin A have different affinities for l igand binding. One of these 
sites is preferentially filled before the other, and binding to this site is cooperative 
with dimerization. Ligand binding to the other, less favored half of the dimer, is 
anti-cooperative with dimerization. 
Conclusions: In dimer complexes, anti-cooperativity of dimerization upon ligand 
binding can be a result of asymmetry, in which two binding sites have different 
affinities for ligands. Such a system, in which one binding site is filled 
preferentially, may be a mechanism by which the cooperativity between ligand 
binding and dimerization is fine tuned and may thus have relevance to the control 
of signal transduction in biological systems. 
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Introduction 
The vancomycin group of glycopeptide antibiotics have a 
heptapeptide backbone with many common residues. 
The backbone is oxidatively cross-linked through 
aromatic side chains, and may carry sugar substituents of 
various types [1,2], as illustrated for ristocetin A in Figure 
1. The molecular basis for their antibacterial action has 
been extensively studied and arises from specific binding 
of the antibiotic to nascent bacterial cell-wall peptides 
terminating in -D-Ala-D-Ala [3,4]. The proposed 
hydrogen-bonding scheme between the cell-wall analogue 
N-acetyl-D-Ala-D-Ala (N-ac-DADA) and ristocetin A is 
shown in Figure 1 [S]. Furthermore, dimerization of these 
glycopeptide antibiotics has been implicated in their 
mode of action [6-B]. 
Recent NMR studies have revealed that both ristocetin A 
(Fig. Za) and eremomycin form asymmetric homodimers 
[5,9]. The glycopeptides A82846B [lo] and ureido- 
balhimycin [ 1 l] also form such structures (as shown by 
NMR and X-ray crystallography, respectively). In all cases, 
the asymmetry arises because the head-to-tail arrangement 
of the peptide backbones in the dimer, which have two- 
fold (C,) rotational symmetry, contrasts with the head-to- 
head arrangement of the sugar substituent on residue 4 of 
the antibiotics (a tetrasaccharide for ristocetin A, Fig. Zb). 
The parallel orientation of the tetrasaccharides results in 
two distinct binding sites; one site is capped by the 
rhamnose of the tetrasaccharide, and the other by the 
arabinose [5]. NMR titration studies with di-N-acetyl+ 
Lys-D-Ala-D-Ala (di-N-ac-KDADA) established that the 
site capped by the rhamnose sugar (designated D1) has a 
higher affinity for cell-wall analogues and binds ligand in 
preference to the site capped by the arabinose sugar 
(designated D,) [5,7]. The difference in ligand binding 
affinities between the two sites was also shown using 
13C-labelled N-ac-DADA [ 121. 
Cooperativity between ligand binding and dimerization 
has previously been observed for all members of the 
vancomycin family that dimerize, apart from ristocetin 
A. The binding of one equivalent of the ligand di-l\r-ac- 
KDADA to ristocetin A has the net effect of slightly 
decreasing the dimerization constant [13]. Ristocetin 
pseudo-agylcone (ristocetin-q), which lacks the 
tetrasaccharide and the mannose attached to the residue 
7 sidechain, displays positive cooperativity between 
dimerization and ligand binding, suggesting that 
the origin of anti-cooperativity for ristocetin A may lie in 
the saccharides [7]. 
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Figure 1 
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Exploded view of the ristocetin A  complex with the cell-wall analogue 
N-ac-DADA. Hydrogen bonds are indicated by dotted lines. The 
aromatic side chains are numbered from the amino terminus. 
Here, we take a quantitative approach to analyze the 
different binding affinities of the two ligand-binding sites 
in the ristocetin A dimer and the anti-cooperative 
relationship between ligand binding and dimerization, 
and discuss the possible relevance of cooperativity to 
biological systems such as signal transduction. 
Results and discussion 
To gain further insight into the anti-cooperativity of 
formation of the ristocetin A dimer we have used two 
spectroscopic probes. The first of these is the rhamnose 
methyl group (Rh, methyl) of the tetrasaccharide on 
the residue 4 sidechain of the antibiotic. Due to the 
asymmetry of the dimer, the Rh, methyl resonances 
appear as two distinct signals in the NMR spectrum. In 
addition, an Rh, methyl signal from the ristocetin A 
monomer is observed between the two dimer resonances. 
Each of these signals are shifted upon complexation with 
ligand. As the two forms of ristocetin A (monomer/dimer) 
are in slow exchange on the NMR timescale, their relative 
populations can be measured as the cell-wall peptide 
analogue is titrated into a solution of the antibiotic. The 
effect of added ligand upon dimerization can thus be 
monitored. The second probe used was the carboxy- 
terminal D-alanine methyl group of di-N-ac-KDADA. This 
methyl group undergoes a characteristic upfield chemical 
shift on binding to the glycopeptide antibiotics, from 
1.4 ppm (for the free ligand) to around 0.6 ppm (bound 
ligand) [7]. The ligand bound to ristocetin A appears as 
two distinct signals corresponding to the two binding sites 
of the dimer. A ligand-b,ound monomer signal is also 
observed and overlaps with the signal of the ligand bound 
to the less favored dimer site [7]. The use of this probe 
yields a more quantitative comparison of the different 
binding affinities of the two binding sites in the dimer. 
The first binding event is cooperative, the second 
anti-cooperative 
Changes in the relative populations of monomeric and 
dimeric ristocetin A were monitored during the stepwise 
addition of up to one molar equivalent of N-ac-DADA. 
Selected spectra are illustrated in Figure 3. In the 
Figure 2 
CH&ONH ,) 
The ristocetin A  dimer is asymmetric. (a) The hydrogen-bonding 
network of the peptide backbone at the ristocetin A  dimer interface 
when bound to di-N-ac-KoAoA. The carboxyl-terminus of the peptide 
backbone on one half of the dimer interacts with the amino-terminus of 
the other half. The arrows represent hydrogen bonds formed between 
the two antibiotic molecules and the dashed lines indicate hydrogen 
bonds between ristocetin A  and di-N-a&DADA. (b) Schematic 
diagram illustrating the physical basis for the asymmetry of the 
ristocetin A  dimer based on 2D NMR [51. The peptide backbones of 
the dimer structure are in an anti-parallel arrangement, in contrast with 
the parallel arrangement of the tetrasaccharides (Rh = rhamnose, 
G = glucose, M  = mannose, A  = arabinose). The rhamnose sugar 
‘caps’ the ligand in the one site, whereas the arabinose of the other 
tetrasaccharide has a similar role in the second site. 
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absence of ligand, the ‘H NMR resonance of the .Rh, 
methyl group of the monomer appears at 1.08 ppm 
(Fig. 3a), whereas in the dimeric form, two signals of 
equal intensity are observed at 0.89 ppm and 1.29 ppm, 
with a relative abundance of monomer and dimer species 
of -1:l. During the first half of the titration (Fig. 3b), 
ligand binding induces the formation of more dimer, 
relative to monomer; however, during the second half of 
the titration (Fig. 3c), ligand binding to the D, site results 
in a reduction in the population of dimer. Thus, although 
the first binding event is cooperative with dimer 
formation, the second binding event is anti-cooperative 
with dimerization. 
The Dl site of the dimer is higher affinity than D2 
To determine the relative ligand binding affinities of the 
two sites in the dimer, we used the carboxy-terminal 
D-alanine methyl group of di-fV-ac-KDADA as a probe. 
The titration was effectively performed in the absence of 
monomer by using a high concentration of antibiotic 
(50 mM). The cell-wall peptide analogue di-N-ac-KDADA 
was used in place of N-ac-DADA as it binds -lo-fold more 
tightly to the antibiotic [ 141. The addition of very small 
amounts of ligand to the concentrated antibiotic solution 
ensured that there were only negligible amounts of the 
doubly bound dimer species present at the beginning of 
the titration. The experiment was conducted at a lower 
temperature (283 K) to reduce the rate of exchange 
between each of the species, such that they are in slow 
(rather than intermediate) exchange. 
After the first addition of ligand (0.06 eq. di-N-ac-KDADA, 
Fig. 4b), it was possible to determine the relative 
populations of the ligand bound into the favored binding 
site, denoted L:D,D2 (ligand bound to the D, site of the 
dimer when the D, site is free), and the less favored 
binding site, denoted D,D,:I, (ligand bound to the D, 
site of the dimer when the D, site is free). The integration 
of the carboxy-terminal D-alanine methyl group of the 
k:D,D2 and DID& complexes at 0.06 equivalents of 
di-N-ac-KDADA shows that the L:D,D2 population is 
greater than that of D,D2:L by a factor of 8 f 2.0. This 
represents a free energy difference of -4.9 + 0.5 kJ mol-’ 
between the two binding sites. 
After addition of 0.23 equivalents of ligand (Fig. 4d), the 
signal representing the doubly bound species, denoted 
L:D,D,:L (resonance from the ligand bound to the D, 
site of the dimer when the D, site is also bound), is 
present. As more ligand is added, the doubly bound dimer 
species, denoted by L:D,D,:L, gradually becomes the 
dominant species. At 1.0 eq. of di-N-ac-KDADA (50 mM), 
the ligand signals L:D1D2:L (resonance from the ligand 
bound to the D, site of the dimer when the D, site is also 
bound) and L:D,D& are seen as doublets at 0.59 and 
0.5 1 ppm respectively (Fig. 41). 
Figure 3 
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Binding of ligand to the first site in the ristocetin A dimer is cooperative 
with dimerization, whereas binding to the second site is anti- 
cooperative. The spectra shown are 500 MHz ‘H NMR spectra (D,O) 
at 295 K of the Rh, methyl signals of (a) ristocetin A alone (3 mM), or 
ristocetin A in the presence of (b) 0.5 equivalents or (c) 1 .O equivalent 
of N-ac-DADA. The peaks labelled with an asterisk are due to the two 
alanine methyl groups in the ligand. M refers to the resonance of the 
Rh, methyl group in the monomer; D, and D, refer to the two 
resonances observed for the Rh, methyl groups in the dimer. 
From these spectra, we could assign each of the bound 
carboxy-terminal D-alanine methyl resonances that arise 
during various stages of the titration and determine the 
relative ligand binding affinities of each half of the dimer. 
The spectra indicate that the Dl site of the ristocetin A 
dimer has much higher affinity for ligand than the D2 site. 
The Dl binding site of the dimer has higher affinity than 
that of the monomer 
To examine the relative affinities of the different binding 
sites on the dimer and the monomer, the cell-wall analogue 
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The D, site of the preformed dimer has 
higher affinity for ligand than the D, site. The 
spectra shown are 600 MHz ‘H NMR 
spectra (CD,CN:D,O, 1:4) at 263 K in the 
region of the carboxy-terminal o-Ala methyl 
resonance of di-Nat-KDADA at various 
equivalence points in a ristocetin A solution 
(50 mM). (a) 0 equivalents of di-N-ac- 
KDADA, (b) 0.06, (c) 0.12, (d) 0.23, (e) 
0.34, (f) 0.44, (g) 0.54, (h) 0.64, (I) 0.73, (i) 
0.63, (k) 0.91, (I) 1 .O equrvalent. D,D, 
denotes the antibiotic dimer with two distinct 
binding sites (see text). LD,D, denotes 
ligand bound to the D, site and D,D,L 
denotes ligand bound to the D, site. 
Underlining represents the bound ligand 
which gives rise to the resonance indicated. 
di-N-ac-[ds]-Lys-D-[dJ-Ala-D-Ala (di-N-ac-[ds]-KD-[d,]- 
ADA) was titrated into a 3 mM solution of ristocetin A at 
283 K. This analogue is a derivative of di-N-ac-KDADA, 
with a deuterated lysine side chain and a deuterated 
methyl group of the penultimate alanine, which function 
to remove the ligand signals that overlap with the Rh, 
methyl signals in the NMR spectra, such as the alanine 
methyl signals evident in Fig. 3b,c. In this titration it was 
possible to use both of the probes described above to 
observe ligand binding events to both sites in the dimer 
and to the monomer (Fig. 5). This titration shows that the 
preferred binding event involves ligand binding to the D, 
site of the dimer (1.33 ppm, Fig. Sb), followed by ligand 
binding to the monomer species (1.03 ppm, Fig. SC), and 
then to the D, site of the dimer (0.93 ppm, Fig. Sd). In 
other words, the D, site of the dimer has the greatest 
affinity for the cell-wall analogue, and the monomer site 
has a greater affinity than the D, site of the dimer. 
The dimerization constants at each stage of the titration 
were determined by integrating the Rh, methyl signals 
from the dimer (from the D, site) and monomer. These 
results are represented by the curve in Figure 6, which 
shows the variation of the dimerization constant with the 
amount of ligand present. Ligand binding to the D, site 
is cooperative with dimerization, raising the dimerization 
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constant from -800 M-l to -1200 M-l. The subsequent 
event of ligand binding into the D, site of the dimer 
reduces the amount of dimer present, shown by the 
decrease in the dimerization constant from -1200 M-l at 
the half way point of the titration to -600 M-l when the 
dimer is fully bound. This clearly demonstrates that 
binding of ligand into the less favored D, site leads to a 
reduction of the dimerization constant, and is thus 
responsible for the overall anti-cooperativity between 
ligand binding and dimerization for ristocetin A. 
The free-energy diagram for ligand binding to ristocetin A 
We have previously shown that an antibiotic dimer, in 
which both binding sites have the same affinity for 
ligand, can display a cooperative enhancement of 
dimerization with ligand binding, and we derived an 
energy diagram to describe this process [5]. Here, we 
have modified the free-energy diagram to describe the 
binding of di-iV-ac-KDADA to the ristocetin A 
asymmetric dimer (with binding sites of different 
affinities) at 283 K (Fig. 7). 
Figure 5 
The free energy level 1 represents two molecules of 
monomeric ristocetin A, ZM, and two unbound molecules 
of the ligand di-N-ac-KDADA, ZL, in their ground- 
state conformations. The free energy difference l-+2 
represents the formation of the asymmetric dimer, DID,, 
from two molecules of monomer. The dimerization 
constant, K,,,, for this process is 83.5 f 150 M-l (AG,,, = 
-15.8 + 0.5 kJ mol-l). 
Similarly, the energy difference 6+7 represents the 
formation of the asymmetric dimer bound to two 
molecules of ligand, formed from two molecules of 
monomeric ristocetin A, each bound to one molecule of 
ligand. This dimerization constant is calculated from the 
relative populations of the ligand-bound monomer 
and dimer species and is 585 + 150 M-l (AG,,, = 
-15.0 * 0.5 kJ mol-‘). 
The ligand binding energies of the antibiotic have been 
measured using UV spectrophotometry. These studies 
were performed at sufficiently low concentration of 
The D, site of the dimer has the greatest 
affinity for di-N-ac-KoAoA, and the monomer 
site has a greater affinity than the D, site of 
the dimer. The spectra shown are 500 MHz 
‘H NMR spectra (D,O) at 283 K in the 
region of the ristocetin A Rh, and carboxy- 
terminal D-Ala methyl resonances in the 
titration of di-N-ac-[d$-Ko-[d,]-ADA into a 
3 mM ristocetin A solution. (a) 0 equivalents 
of di-N-ac-[dsl-Ko-[d,]-ADA, (b) 0.17, (c) 
0.39, (d) 0.84, (e) 1 .O equivalent. M denotes 
antibiotic monomer and D,D, denotes the 
antibiotic dimer with the two distinct binding 
sites (see text). LD,D, denotes ligand bound 
to the D, site and D,D,L denotes ligand 
bound to the D, site. L represents the bound 
ligand which gives rise to the carboxy- 
terminal Ala methyl resonance indicated. M 
and 51 represent the antibiotic monomer or 
the monomeric partner within the dimer, 
respectively, that gives rise to the Rh, methyl 
resonance indicated. 
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Figure 6 
500 I I I 
0 0.215 0.55 0.82.5 1.1 
Equivalents of di-N-ac-[dd-Ko -[d,]-ADA added 
Ligand binding to the D, site is cooperative, whereas subsequent 
binding to the D, site is anti-cooperative. A plot of the change in binding 
constant (hi,,,) between ristocetin A and di-N-ac-[d,l-Ko-[dsl-ADA, as a 
function of added di-Mac-[d J-Ko-[dJ-ADA is shown. Binding to the D, 
site raises Kdi,,,; subsequent binding to the D, site reduces the amount 
of dimer present as indicated by the reduction in hi,,,. 
ristocetin A that it was essentially all monomer. The 
binding constant of monomeric ristocetin A with di-N-ac- 
KDADA, represented by the free energy difference 1+5 is 
K,,, = 8.6 * 1.9 x lo5 M-l (AG,,, = -26.7 rt 0.5 kJ mol-‘). 
The ligand-binding energies of the D, and D, sites of the 
antibiotic, when the remaining site is free, were 
determined by measuring the relative populations of the 
ligand bound signals and the free antibiotic signals (see 
experimental section for more detail); these are AG,,, = 
-23.0 * 1.0 kJ mol-’ and AG,,, = -27.9 * 1.0 kJ mol-‘. 
Figure 7 
Where free energies could not be experimentally 
determined (for example the binding energies of 
di-N-ac-KDADA into the Dl or D2 sites of dimer with 
the other site already occupied) values were calculated 
from the free energy diagram. These free energies were 
calculated as AG,,, = -29.6 * 1.4 kJ mol-1 and 
AG,,, = -24.7 f 1.4 kJ mol-‘. 
Consequences of the free-energy diagram 
The energy diagram (Fig. 7) illustrates the cooperativity 
between dimerization and ligand binding to the D, site. 
This site has a greater ligand binding energy (-X7.9 
kJ mol-‘) than the monomer (M) site (--26.7 kJ mol-‘). 
Upon the subsequent filling of the D, site, however, 
dimerization becomes anti-cooperative, as this site has a 
lower ligand binding energy (-24.7 kJ mol-l) than the 
monomer site. This is illustrated clearly by the decrease in 
the dimer population upon the subsequent binding of 
ligand to the less favored site, D, (Fig. 6). 
Significance 
The role of dimeric structures in biological processes is 
widespread and well known (for example, [15-171). The 
interdependence between dimerization and binding to 
another molecule (e.g., ligand or cofactor) is often 
important in physiological processes. Perhaps the most 
well known example of this interdependence is that 
displayed by hemoglobins, where the affinity for oxygen 
and the sigmoidal shape of the binding curve is 
dependent upon the strength of the dimer interaction of 
the protein, the pH, and the concentrations of 
diphosphoglycerate (DPG) and chloride ions [ 161. The 
oxygen affinity of the related molecule myoglobin, which 
exists as a monomer, does not display the same 
dependence on the concentration of H+, DPG or Cl- 
\ 
AG,,5 =-26.7f 0.5 kJ mol-' 
AG 2,4= -27.9 f 1.0 kJ ml-' 
5 
f 
L:M+M+L 
The free-energy diagram for di-N-ac-KoAoA 
binding to ristocetin A. The left half of the 
energy diagram follows the process of 
dimerization and the subsequent binding of 
two ligand molecules. The right half of the 
diagram follows the process of ligand binding 
to monomer, followed by dimerization. The 
differences between the energy levels were 
determined as described in the text. 
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[ 171. Thus, to gain any advantage from these factors, the 
oxygen carrier must exist as a dimer. 
The dimeric structures of the vancomycin group of 
antibiotics studied to date (with the exception of the 
monomeric teicoplanin and the ristocetin A dimer 
considered here) have been shown to facilitate 
cooperativity between dimerization and the binding of the 
natural ligand [7]. In other words, ligand binding to 
antibiotic dimer is more favorable than to monomer and 
dimerization is more favorable when l&and is bound. This 
cooperativity is believed to enhance the activity of the 
antibiotic, particularly when an antibiotic dimer can bind 
simultaneously to two mucopeptide cell wall precursors 
that are attached to the same bacterial cell membrane [Sl. 
Here, we have investigated the overall anti-cooperative 
nature of the asymmetric homodimer of ristocetin A, an 
antibiotic that has distinct binding affinities for ligand in 
each half of the dimer. We have shown that binding to 
one half of the dimer remains cooperative such that 
ligand binding to this dimer half is stronger than to 
antibiotic monomer. Ligand binding to the other half of 
the dimer, however, is less favorable than to the 
monomer such that when the less favorable binding site 
of the dimer is tilled, the dimerization constant is reduced 
- an anti-cooperative effect. An asymmetric dimer with 
two distinct affinities for ligand may be a common 
mechanism for the fine tuning of activity or physiological 
response. For the bacterial aspartate receptor, which is a 
dimeric receptor, ligand induced asymmetry of the dimer 
modulates the affinity for aspartate 1181. Controlling the 
interdependence of dimerization and ligand binding in 
this way avoids the need to alter the residues which 
directly form the binding site. Changing these residues 
without causing drastic changes in activity may be very 
difficult, but more subtle control may be exerted if 
structural changes are made that indirectly affect 
dimerization and ligand binding 1181. 
Materials and methods 
Materials 
The antibiotic ristocetin A was kindly provided by Abbott 
Laboratories (Chicago) as the sulphate salt. o-Alanine, D-alanyf-D- 
alanine and di+/-acetyl-lysyl-D-alanyl-D-alanine were purchased from 
Sigma. o-[dsl-Alanine and L-id,]-lysine were purchased from 
Eurisotope. Di-terf-butyldicarbonate was purchased from Aldrich and 
HBTU (2-(1 H-benzotriazole-1 -yl)-1 ,1,3,3-tetramethyluronium hexa- 
fluorophosphate) was purchased from Novabiochem. 
One-dimensional ‘H NMR spectra were recorded on a Bruker DRX 
500 MHz spectrometer and a Varian Unity Plus 600 MHz spectrometer 
using a standard pulse sequence. Spectra were recorded with 32 K 
data points and referenced with respect to either residual protio 
solvent (6 = 7.26 ppm for CDCI,, 6 = 2.52 ppm for da-DMSO) or 
internal 3-(trimethylsilyl)-1 -propanesulphonate (TSP, 6 = 0.00 ppm). 
Ristocetin A was prepared for NMR titration studies by lyophilization 
twice from D,O, followed by dissolution in a pD 7.0 buffer (KD,PO, 
(0.1 M)/NaOD (0.1 M)). Ligand samples were similarly prepared but 
were finally taken up in the buffered ristocetin A solution (200 ~1) to 
maintain the same antibiotic concentration during titrations. All 
titrations were performed using stepwise additions of the ligand 
solution (5 or 10 t.~l aliquots) into antibiotic solution. All pD sample 
readings were measured with a Corning 125 pH meter equipped with 
a combination glass electrode at 25 “C. The pD values quoted 
throughout are pH meter readings, and no corrections have been made 
for isotope effects. 
The determination of the binding constant between ristocetin A and 
di-N-ac-KoAcA was done using a UVIKON 940 dual beam 
spectrophotometer at 283 K. Ristocetin A (1.08 mg, 0.50 pmol) was 
taken up in aqueous buffer (0.1 M KH,PO,/NaOH, pH 7.0, 10 ml). 
Two ligand solutions (1.5 ml, 190 mM) were prepared, one from the 
antibiotic solution and the other from the buffer solution. The X,, for 
ristocetin A was determined by measuring the UV spectrum with 
antibiotic solution in the sample beam and a buffer solution in the 
reference beam. The A,,, for the antibiotic-ligand complex was 
determined by measuring the UV spectrum after the addition of 1 ml of 
ligand/antibiotic solution to the sample cell, and 1 ml of ligandjbuffer 
solution to the reference cell. The greatest differences in A between 
the antibiotic and antibiotic-ligand complex fell in the region of 
280-294 nm, and a smaller difference in the region of 240-250 nm. 
The titration was performed by adding aliquots of the ligand/antibiotic 
and ligandlbuffer solutions to the sample and reference cell 
respectively, and measuring the absorbance at 244, 246, 280, and 
284 nm after each addition of ligand. The data at 244 and 246 nm 
were added together and subtracted from the sum of the data at 280 
and 284 nm. The resulting data set was plotted against the 
concentration of the ligand added, resulting in a smooth binding curve. 
This curve was analyzed using the proprietary non-linear curve-fitting 
routine of Abelbeck software’s Kaleidagraph version 2.1.3. 
Preparation of N-acetyh-a/any/-o-alanine 
D-Alanyl-D-alanine (100 mg, 0.62 mmol) was dissolved in water (1 ml) 
and distilled acetic anhydride (1 ml) was added. The solution was 
stirred for 2 h at room temperature and the solvent was removed under 
reduced pressure to give an oil. Repeated lyophilization of the residue 
yielded N-acetyl-o-alanyl-o-alanine as a white powder (124 mg, 98 o/o) 
which was used without further purification. 
Preparation of t-Boc-D-[d3]-alanine 
c-[d$-Alanine (300 mg, 3.30 mmol) and di-t-butyldicarbonate (840 mg, 
3.80 mmol) were dissolved in a mixture of acetonitrile (1.5 ml) and 
sodium hydroxide solution (3 M, 4 ml). The solution was stirred for 3 h, 
after which time further sodium hydroxide solution (3 M, 1 ml) was 
added so as to maintain the pH above 9.5. Stirring was continued 
overnight and the reaction mixture was then washed with ether 
(2 x 20 ml). The aqueous layer was then acidified with hydrochloric acid 
solution (3 M) to pH 1 and was extracted with ethyl acetate (3 x 20 ml). 
The combined ethyl acetate extracts were washed with brine (30 ml), 
dried over anhydrous sodium sulfate and filtered. The filtrate was 
evaporated to dryness under vacuum to yield t-Boc-o-Ids]-alanine 
(552 mg, 88 %) as an off-white waxy solid which was used without 
further purification. 
Preparation of t-Boc-D-alanine benzyl ester 
f-Boc D-alanine (8.0 g, 42 mmol) was dissolved in ethyl acetate (140 ml) 
to which benzyl bromide (12.2 g, 71 mmol) and triethylamine (7.7 g, 
76 mmol) were added. The resulting mixture was heated at reflux for 
18 h. The mixture was then filtered and the residue was washed with 
ethyl acetate (2 x 30 ml). The combined filtrates were then washed with 
hydrochloric acid solution (1 M, 2 x 80 ml), water (80 ml), sodium 
hydrogen carbonate solution (10 o/, w/v, 2 x 80 ml) and brine (80 ml). 
The organic layer was then dried over anhydrous sodium sulfate, filtered 
and evaporated to dryness to afford t-Boc-o-alanine benzyl ester (8.3 g, 
71 o/o) as a colorless oil, which was used without further purification. 
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Preparation of t-Boc-D-[dd-aianykD-alanine benzyl ester 
t-Boc-o-alanine benzyl ester (780 mg, 2.80 mmol)  was dissolved in a 
mixture of dichloromethane (4 ml) and a solution of anhydrous 
hydrogen chloride in dioxane (4 M, 4 ml) and stirred for 2 h. The solvent 
was then removed to afford crude D-alanine benzyl ester hydrochloride 
as a white solid. The crude material was then dissolved in 
dichloromethane (4 ml) and N,N-diisopropylethylamine (400 mg, 3.09 
mmol)  and added to a mixture of t-Boc-o-Ids]-alanine (540 mg, 2.80 
mmol), N,N-diisopropylethylamine (410 mg, 3.17 mmol)  and HBTU 
(1.25 g, 3.30 mmol)  in dichloromethane (6 ml), which had previously 
been stirred for 10 min. The resulting solution was stirred at room 
temperature for 30 min and then washed with hydrochloric acid 
solution (3 M, 3 x 20 ml), sodium hydrogen carbonate solution 
(10 %  w/v, 2 x 20 ml), brine (30 ml), dried over anhydrous sodium 
sulfate, filtered and evaporated to dryness. The residue obtained was 
then chromatographed over silica (chloroform) to afford t-Boc-o-[ds]- 
alanyl-D-alanine benzyl ester (790 mg, 80 %) as a white waxy solid. 
‘H NMR (500 MHz; CDCl3; 300 K) 6 1.40 (3 H, d, J 7.2 Hz), 1.43 (9 
H, s), 4.12-4.17 (1 H, m), 4.61 (1 H, app quin), 4.97-5.02 (1 H, m), 
5.16 (2 H,ABq,JAe 7.8 Hz), 6.60-6.70 (1 H, m), 7.31-7.38 (5 H, m). 
Preparation of di-t-Boc-L-id&ysine 
L-[d,]-Lysine monohydrochloride (40 mg, 0.21 mmol)  and di-t-butyl- 
dicarbonate (110 mg, 0.50 mmol)  were dissolved in a mixture of 
acetonitrile (250 ml) and sodium hydroxide solution (3 M, 350 ml) and 
the pH of the solution was adjusted to greater than 9 by the addition of 
further sodium hydroxide solution (3 M, 350 ml). The mixture was stirred 
overnight and then washed with ether (2 x 10 ml) and the aqueous layer 
was acidified to pH 1 by the addition of hydrochloric acid solution (3 M), 
which resulted in a milky solution. The acidified aqueous layer was then 
extracted with ethyl acetate (3 x 10 ml) and the combined extracts were 
dried over anhydrous sodium sulfate, filtered and evaporated to dryness 
to afford crude di-t-Boc-L-[d,]-lysine as a pale brown glassy solid 
(68 mg, 91 O/o) which was used without further purification. 
Preparation of di-t-Boc-[d$-lysyl-D-[dd-a/any/-D-alanine 
benzyl ester 
f-Boc-o-[d,]-alanyl-o-alanine benzyl ester (65 mg, 0.18 mmol)  was 
dissolved in a mixture of dichloromethane (1 ml) and a solution of 
anhydrous hydrogen chloride in dioxane (4 M, 1 ml) and stirred for 2 h. 
The solvent was then removed to afford crude D-[d,]-alanyl-D-alanine 
benzyl ester hydrochloride as a white solid. This residue was then 
taken up in a mixture of dichloromethane (1 ml) and N,N-diiso- 
propylethylamine (a sufficient amount to solubilize the hydrochloride 
salt) and added to a solution of di-f-Boc-Ids]-lysine (68 mg, 
0.19 mmol), HBTU (95 mg, 0.25 mmol)  and I+‘+diisopropylethylamine 
(100 mg, 0.77 mmol)  in dichloromethane (1 ml), which had previously 
been stirred for 10 min. The resulting solution was stirred for 2 h and 
then washed with hydrochloric acid solution (3 M, 2 x 20 ml), sodium 
hydrogen carbonate solution (10 %  w/v, 2 x 20 ml), brine (30 ml), dried 
over anhydrous sodium sulfate, filtered and evaporated to dryness. 
The residue obtained was then chromatographed over silica 
(methanol:chloroform, 5:95) to afford di-f-Boc-[de]-lysyl-D-ids]-alanyl-o- 
alanine benzyl ester (77 mg, 73 o/o) as a white crystalline solid. ‘H NMR 
(500 MHz; CDCI,) 6 1.36-1.45 (21 H, m), 3.97-4.05 (1 H, m), 4.50 
(1 H, d, J 7.5 Hz), 4.56 (1 H, app quin), 4.85 (1 H, bs), 5.15 (2 H, ABq, 
JAB 13.5 Hz), 5.30 (1 H, bs), 6.84-6.86 (1 H, m), 6.97-6.99 (1 H, m), 
7.30-7.36 (5 H, m). 
Preparation of di-N-acetyl-[d$-iysyi-o-[dd-a/any/-D-alanine 
benzyl ester 
Di-t-Boc-[d,]-lysyl-o-[ds]-alanyl-o-alanine benzyl ester (77 mg, 
0.13 mmol)  was dissolved in dichloromethane (2 ml) and a solution of 
anhydrous hydrogen chloride in dioxane (4 M, 2 ml) and stirred for 
90 min. The solvent was then removed to afford crude L-[d,]-lysyl-D- 
[ds]-alanyl-D-alanine benzyl ester dihydrochloride. This was then 
suspended in a mixture of dichloromethane (5 ml) and N,N-diiso- 
propylethylamine (750 mg, 5.80 mmol)  and acetic anhydride (200 mg, 
1.96 mmol)  and stirred for 3 h. The mixture was then evaporated to 
dryness and chromatographed over silica (methanol:chloroform 1:4). 
The major band was collected and evaporated to dryness to afford di- 
N-acetyl-[d,]-lysyl-o-[d,]-alanyl-D-alanine benzyl ester as a white solid 
(45 mg, 73 46). ‘H NMR (500 MHz; ds-DMSO) 6 1.30 (3 H, d, 17.3 
Hz), 1.75 (3 H, s), 1.80 (3 H, s), 4.14 (1 H, d, J 7.5 Hz), 4.25-4.32 (2 
H, m), 5.09 (2 H, ABq, 13.0 Hz), 7.30-7.39 (5 H, m), 7.71 (1 H, bs), 
7.96 (1 H, d, J 7.5 Hz), 8.1 1 (1 H, d, J 7.9 Hz), 8.23 (1 H, d, J 7.0 Hz). 
Preparation of di-N-acetyl-[d$-iysyl-D-[dd-a/any/-D-alanine 
Di-N-acetyl-[ds]-lysyl-o-[d,]-alanyl-o-alanine benzyl ester (45 mg, 
0.09 mmol)  was dissolved in absolute ethanol (10 ml) and PdlC (5 46, 5 
mg) was added and the reaction mixture was hydrogenated at 1 atm for 
12 h. The mixture was then flushed with nitrogen, filtered through celite 
and evaporated to dryness. The solid obtained was then lyophilized from 
deionized water to afford di-N-acetyl-[d,]-lysyl-o-[ds]-alanyl-o-alanine as 
a white solid (35 mg, 96 %). ‘H NMR (500 MHz; 60 %  D,O/H,O) 6 
1.31 (3 H, d, J 7.2 Hz), 1.88 (3 H, s), 1.94 (3 H, s), 4.11-4.15 (1 H, m), 
4.16-4.22 (1 H, m), 4.23-4.26 (1 H, m), 7.82 (1 H, bs), 8.04 (1 H, d, J 
6.5 Hz), 8.12 (1 H, d, J 8.5 Hz), 8.27 (1 H, d, J 6.5 Hz). 
Determination of the dimerization constant of ristocetin A 
The dimerization constants for ristocetin A  when free (K,,s) and bound 
to di-N-ac-KoAoA (Ks,$ were determined by measuring the relative 
integrals of the Rh, methyl NMR signals for monomer and dimer 
species obtained at different concentrations of antibiotic at 283 K. The 
relative integrals were determined by cutting and weighing the signals 
from the plotted spectra. The concentration of dimer was plotted 
against the total concentration of antibiotic, and the resulting curve 
was analyzed using the proprietary non-linear curve fitting routine of 
Abelbeck Software’s Kaleidagraph version 2.1.3. 
Determination of the binding constant for the D, site 
The binding constant of di-N-ac-KoAoA to the D, site of the 
ristocetin A  dimer, with the D, site free, was determined using the 
following equation: 
[LD, D,l 
K , &- 
2’4 = [D,Ds][L] 
The concentrations were determined from NMR data from a solution 
obtained by adding 0.06 equivalents of di-N-ac-KoAoA to a 50 m M  
ristocetin A  solution. The total dimer population was measured by 
determining the average integral of the D, and D, signals and this total 
weight was taken to be equivalent to 25 mM.  
[L] is the free ligand concentration, and under these conditions this 
concentration is difficult to measure since most of the ligand is bound 
to the antibiotic. Since the total ligand concentration was known (the 
amount of ligand added, 3 mM),  and the two ligand-bound dimer 
species are measurable from the NMR spectra, [L] could be 
determined using the following relationships: 
D,,,,,l = D, D21 + LD, D,l+ ID, D&l 
[Jotdl = Ll + LD,D,l + [D,D,Ll 
Once this binding constant (ligand binding into D, with D, free) was 
determined, the binding constant for ligand into the D, site with D, 
free was attainable, as the free energy difference between LD, D, and 
D, D,L was known (AG,,, = -4.9 &  0.5 kJ mol-l). 
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